CAR T-cell Therapy

CompetitiveJuly 27, 2026

Phase I/II Trial of CD20 CAR T-Cell Therapy for Relapsed/Refractory B Cell Lymphoma

A Phase I/II study is underway to evaluate the safety and efficacy of autologous T cells engineered to express CD20-specific CAR in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

Companies

Assets

Recent signals(19)

Study on Anakinra to Reduce Cytokine Release Syndrome in B-ALL CAR T-Cell Therapy

Phase I Trial of E-SYNC CAR T Cells for EGFRvIII Positive Glioblastoma

Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma Initiated

Phase 1 Trial of CD19/BCMA CAR-γδT Cell Therapy in Autoimmune Diseases

Phase 1 Trial of TSLPR-CART in Refractory B-ALL Shows Promise for Targeting TSLPR Overexpression

Phase I Trial of EGFR/IL13Rα2 CAR T Cells for Recurrent High-Grade Gliomas

Study on Long-term Effects of Pediatric CAR-T Cell Therapy Initiated

Phase I/II Trial of CD20 CAR T-Cell Therapy for Relapsed/Refractory B Cell Lymphoma

NCI Trials B7-H3 CAR T Cell Therapy for Refractory Small Cell Lung Cancer

AstraZeneca Initiates Phase 1b/2 Trial of AZD0120 for Relapsed/Refractory Multiple Myeloma

CAR-T Cell Therapy for ALL: Emerging Research Trends and Focus Areas Identified

Phase 1 Study of Allogeneic CD30.CAR-EBVSTs in Relapsed/Refractory Lymphomas

Phase 1b/2 Study of JNJ-90014496 for B-Cell Non-Hodgkin Lymphoma Initiated by Janssen

Phase I Trial of CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies

Phase I Trial of CAR T Cells with Chlorotoxin for MMP2+ Recurrent Glioblastoma

NCI Trials CD19/CD22 CAR T Cells for Refractory B Cell Malignancies in Young Patients

BrainChild Bio Initiates CAR T Therapy Study for DIPG Patients

Phase 2 Trial of Lisocabtagene Maraleucel Targets Minimal Residual Disease in Large B-cell Lymphoma

First-in-human Phase 1 Study of ML261 in R/R SCLC and NECs Initiated by Moonlight Bio

Upcoming catalysts

Indications

Get signals before the market moves